People · Operator
Named in public records as an officer, director or promoter · active 2007–2023 · Biotechnology, Pharmaceuticals, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. | — | Biotechnology | Series C | $178.6M | $433.3M | 2019 |
| Homology Medicines, Inc. | — | Pharmaceuticals | Series C | $127.1M | $2.9B | 2017 |
| Scientia Vascular, Inc. | — | Other Health Care | Series C | $55.0M | $48.2M | 2023 |
| Cerebral Therapeutics, Inc. | — | Pharmaceuticals | Series B | $31.0M | $680.1M | 2018 |
| Avadhi Finance & Technology Inc | — | Other Technology | Seed | $2.7M | $91.1M | 2007 |
Mahendra Shah at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mahendra Shah on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Kush Parmar | 1 | 10 |
| Cameron Wheeler | 1 | 9 |
| James Healy | 1 | 8 |
| Richard Miller | 1 | 8 |
| Peter Moldt | 1 | 6 |
| Brad Smith | 1 | 6 |
| Paul Stone | 1 | 5 |
| Edgar G Engleman | 1 | 5 |
| David Bearss | 1 | 5 |
| MATTHEW HAMMOND | 1 | 5 |
| Mahendra G. Shah | 1 | 3 |
| Ashish Khanna | 1 | 3 |
| Daniel Abrams | 1 | 3 |
| Warren Lammert | 1 | 3 |
| Chih-Ping Liu | 1 | 2 |
| Stephen Farr | 1 | 2 |
| David Dornan | 1 | 2 |
| Rajan Shah | 1 | 2 |
| Ashish G. Khanna | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.